Clinical Trial Update: FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC [Phase 2]

View source ↗

Summary

Phase 2 trial assessing FOLFIRI plus cetuximab and avelumab in RAS wild-type colorectal cancer has completed, with results reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Avelumab (avelumab)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Treatment Related Cancer | Phase 2 | Status: COMPLETED